专题：CAR-T cell therapy research

This cluster of papers focuses on Chimeric Antigen Receptor (CAR) T cell therapy, a form of immunotherapy that uses genetically engineered T cells to target and destroy cancer cells. The papers cover various aspects of CAR T cell therapy, including its application in treating leukemia, lymphoma, and solid tumors, the management of cytokine release syndrome associated with this therapy, and the long-term efficacy and safety of CAR T cell treatment.
最新文献
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study

article Full Text OpenAlex

In vivo site-specific engineering to reprogram T cells

article Full Text OpenAlex

BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial

article Full Text OpenAlex

CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial

article Full Text OpenAlex

Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial

article Full Text OpenAlex

Intraperitoneal programming of tailored CAR macrophages via mRNA lipid nanoparticle to boost cancer immunotherapy

article Full Text OpenAlex

Scarless circular mRNA-based CAR-T cell therapy elicits superior antitumor efficacy

article Full Text OpenAlex

Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia

article Full Text OpenAlex

CAR-macrophages in solid tumors: promise, progress, and prospects

article Full Text OpenAlex

Metabolic reprogramming of CAR T cells: a new frontier in cancer immunotherapy

article Full Text OpenAlex

近5年高被引文献

Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in /www/wwwroot/tuan.pub/openalex/domainsTreeTopics_TopCited.php on line 49
Long-term outcomes following CAR T cell therapy: what we know so far

review Full Text OpenAlex 1396 FWCI66.0702

CAR T cells produced in vivo to treat cardiac injury

article Full Text OpenAlex 1388 FWCI92.424

CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up

article Full Text OpenAlex 1107 FWCI167.0196

Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus

article Full Text OpenAlex 1104 FWCI121.5624

Decade-long leukaemia remissions with persistence of CD4+ CAR T cells

article Full Text OpenAlex 925 FWCI71.6703

CAR T Cells Produced in vivo to Treat Cardiac Injury

book-chapter Full Text OpenAlex 920 FWCI535.1077

GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas

article Full Text OpenAlex 830 FWCI63.0954

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

article Full Text OpenAlex 823 FWCI144.521

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

article Full Text OpenAlex 805 FWCI61.3803

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

article Full Text OpenAlex 781 FWCI136.5996